The ultimate ASX growth shares to buy with $2,000 in March

Analysts think these shares could be among the best of the best for growth investors.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of ASX growth shares for investors to choose from on the Australian share market.

To narrow things down, let's take a look at some that could be considered among the best of the best.

Here's why analysts think they could be top picks for a $2,000 investment:

Ecstatic woman looking at her phone outside with her fist pumped.

Image source: Getty Images

Pro Medicus Limited (ASX: PME)

Pro Medicus is one of the most explosive ASX growth shares on the Australian share market.

For many years, the health imaging technology company has been growing at a rapid rate thanks to increasing demand for its Visage solution.

Bell Potter believes this strong form can continue. It said:

The PME full stack solution continues to wipe the floor with competitors – 10 contract announcements in the LTM including two new academic medical centres clients. FY25/26 revenues upgraded by 4% and 2% respectively. In addition we expect further growth in the cardiology space with the first small scale implementation to take place in April 2025.

Bell Potter has a buy rating and $330.00 price target on its shares.

ResMed Inc. (ASX: RMD)

Goldman Sachs thinks that ResMed could be an ASX growth share to buy with $2,000.

It is a leading sleep disorder treatment company with a world class portfolio of devices and software to treat sleep apnoea and other conditions.

Sleep apnoea is a huge market, with an estimated 3 in 10 men and 1 in 5 women having the condition. And with awareness increasing thanks to technology, ResMed is in a very strong position as the clear industry leader. Goldman Sachs said:

Our Buy recommendation on RMD is premised on (1) Ongoing robust new patient growth for CPAP therapy despite the market entry of GLP-1 drugs to treat OSA, (2) Further RMD market share gains, building on its #1 global market position, (3) Expansion of the OSA market in regions outside of the US. We believe the stock's current trading multiple is unjustified based on its growth outlook.

Goldman has a conviction buy rating and $49.00 price target on its shares.

WiseTech Global Ltd (ASX: WTC)

Finally, WiseTech Global could be another ultimate ASX growth share to buy.

It is a leading global provider of software solutions to the logistics services industry with its CargoWise One platform.

WiseTech Global has been growing at a rapid rate for many years thanks to strong demand for CargoWise One. And while product launch delays and CEO indiscretions have weighed on sentiment in recent months, the future remains very bright for the company and its shares.

It is for this reason that Goldman Sachs is tipping it as a buy. It said:

We are positive on WiseTech's strong competitive position which contributes to efficiency gains for LGFF's. Over the short-to-medium term we expect WiseTech's earnings profile to benefit from new product releases such as Container Transport Optimizer, as well as the company continuing to grow penetration of their core business.

We expect WiseTech will continue to focus on product development over the long-term, which should underpin margin expansion and earnings growth. Hence, with the risk/reward profile skewed to the upside we are Buy rated.

Bell Potter currently has a buy rating and $128.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in Pro Medicus, ResMed, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, ResMed, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed and WiseTech Global. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Growth Shares

2 incredible ASX 200 shares to buy and hold for 10 years

These shares could help you build wealth over the long term.

Read more »

Excited couple celebrating success while looking at smartphone.
Growth Shares

3 buy-rated ASX growth shares tipped to rise 30%+

Analysts are bullish on these names. Here's what you need to know.

Read more »

Piggy bank rocketing.
Growth Shares

SpaceX starts trading today. Here's what ASX investors need to know

Here's how ASX investors can gain exposure.

Read more »

A young man looks like he his thinking holding his hand to his chin and gazing off to the side amid a backdrop of hand drawn lightbulbs that are lit up on a chalkboard.
Growth Shares

Where to invest $50,000 in ASX 200 shares in FY27

These shares could be worth considering ahead of the new financial why. Let's look at the reasons why.

Read more »

A smartly-dressed businesswoman walks outside while making a trade on her mobile phone.
Growth Shares

3 ASX growth shares I'd buy to build long-term wealth

These businesses help families, advisers, consumers, or households solve real problems, and I think each has room to grow.

Read more »

Rising arrow on a piggy bank with a woman holding it and smiling.
Growth Shares

2 ASX growth shares to buy with big growth potential!

Analysts are excited about the prospects of these businesses…

Read more »

Three excited business people cheer around a laptop in the office
Growth Shares

3 amazing ASX growth shares to buy and hold forever

Analysts think these shares could be buys for growth investors.

Read more »

A man sits at his home desk calculating tax on a calculator.
Growth Shares

Why Xero shares could be the best tech pick on the ASX right now

The market may be making a mistake with Xero shares.

Read more »